BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11265126)

  • 1. [Dynamic MR imaging of liver lesions with superparamagnetic iron oxide (SH-U-555A)].
    Saito K; Ishida J; Ito N; Kakizaki D; Kotake F; Abe K
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Feb; 61(3):84-8. PubMed ID: 11265126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity.
    Tanabe M; Ito K; Shimizu A; Fujita T; Onoda H; Yamatogi S; Washida Y; Matsunaga N
    Magn Reson Imaging; 2009 Jul; 27(6):801-6. PubMed ID: 19144487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Superparamagnetic iron oxide particles: what value has the T1 effect in the MR diagnosis of focal liver lesions?].
    Urhahn R; Adam G; Busch N; Chen JH; Euringer W; Günther RW
    Rofo; 1996 Oct; 165(4):364-70. PubMed ID: 8963049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
    Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
    Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
    Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S
    AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.
    Lee JM; Kim CS; Youk JH; Lee MS
    Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic MRI with SPIO: detection and characterization of focal liver lesions.
    Reimer P; Tombach B
    Eur Radiol; 1998; 8(7):1198-204. PubMed ID: 9724439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules.
    Chen RC; Lii JM; Chou CT; Chang TA; Chen WT; Li CS; Tu HY
    J Formos Med Assoc; 2008 Oct; 107(10):798-805. PubMed ID: 18926947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.
    Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D
    Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
    Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
    AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging.
    Kim YK; Kim CS; Kwak HS; Lee JM
    J Magn Reson Imaging; 2004 Nov; 20(5):826-37. PubMed ID: 15503325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration--preliminary clinical experience with dynamic T1-weighted MR imaging.
    Reimer P; Müller M; Marx C; Wiedermann D; Muller R; Rummeny EJ; Ebert W; Shamsi K; Peters PE
    Radiology; 1998 Dec; 209(3):831-6. PubMed ID: 9844683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [T1-weighted dynamic MRI with new superparamagnetic iron oxide particles (Resovist): results of a phantom study as well as 25 patients].
    Müller M; Reimer P; Wiedermann D; Allkemper T; Marx C; Tombach B; Rummeny EJ; Shamsi K; Balzer T; Peters PE
    Rofo; 1998 Mar; 168(3):228-36. PubMed ID: 9551108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in hepatic uptake and distribution of organ-specific superparamagnetic MRI contrast media: clinical findings and classification according to pathogenesis.
    Macarini L; Marini S; Murrone M; Ettorre GC
    Radiol Med; 2004; 108(1-2):92-106. PubMed ID: 15269693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma.
    Tanimoto A; Kuribayashi S
    Eur J Radiol; 2006 May; 58(2):200-16. PubMed ID: 16414230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
    Mergo PJ; Helmberger T; Nicolas AI; Ros PR
    AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
    Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
    Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions.
    Namkung S; Zech CJ; Helmberger T; Reiser MF; Schoenberg SO
    J Magn Reson Imaging; 2007 Apr; 25(4):755-65. PubMed ID: 17335040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Focal liver lesions. A comparison between magnetic resonance under base conditions and after a superparamagentic contrast medium].
    Finazzo M; Midiri M; Gallo C; Bartolotta TV; Luca A
    Radiol Med; 1998 Jun; 95(6):599-607. PubMed ID: 9717542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.